§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇳🇴Norway	🇺🇸United States
Authority & dossier
Regulatory authority	DMP (formerly NoMA / SLV)	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	EMA (Centralised Procedure — mirrored automatically), EEA Member States (DCP / MRP), EU CMDh	—
Lead pathway (timeline & fees) — EU Centralised Procedure (mirrored nationally) · New Drug Application — 505(b)(1)
Pathway name	EU Centralised Procedure (mirrored nationally)	New Drug Application — 505(b)(1)
Approval timeline	210–300 days	304–365 days
Application fee	EUR 350,000	USD 4,310,002
Annual renewal	EUR 130,000	USD 416,734
Local representative	Not required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	No	No
Local responsible person	Yes	Yes
RP role	QPPV established in the EEA (any EEA member) per EU GVP Module I; QPPV is the contact for DMP pharmacovigilance. Norwegian-language pharmacovigilance literature monitoring required for products marketed in Norway. A Pharmacovigilance System Master File (PSMF) location must be declared.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Accelerated Assessment (EMA CP), Conditional Marketing Authorisation (CMA), PRIME (Priority Medicines) +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	EU variations framework (Commission Regulation 1234/2008 as amended) — Type IA / IAIN (do-and-tell), Type IB (tell-wait-do), Type II (prior approval), Extensions and Article 61(3) notifications. DMP processes variations for nationally / DCP / MRP authorised products; EMA processes variations for centrally-authorised products with DMP receiving mirror decisions.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Standard renewal at 5 years post first authorisation; subsequent unlimited validity unless DMP / EMA decides on safety grounds to require further renewal. CMAs renewed annually until conversion to full MA.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	EU pharmacovigilance framework (Directive 2010/84/EU and Regulation 1235/2010) implemented via Norwegian Medicines Act and DMP guidelines. EudraVigilance reporting mandatory; PSURs per EURD list submitted to EMA PSUSA. Norwegian Adverse Drug Reactions Register (Bivirkningsregisteret) operated by DMP. PRAC participation by DMP. Norwegian Med-Safety mobile app for patient reporting.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–106 days	30–30 days
GCP standard	ICH E6(R3) GCP; EU Clinical Trials Regulation 536/2014 (EU CTR); Norwegian Medicines Act and Regulation on Clinical Trials of Medicinal Products for Human Use	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	DMP (single-technology assessments — STA) and Norwegian Institute of Public Health / Folkehelseinstituttet — FHI (multi-technology assessments — MTA), under the Nye Metoder (New Methods) framework. Decisions for hospital medicines made by Beslutningsforum (the Decision Forum of the four Regional Health Authority CEOs); decisions for outpatient blue-prescription medicines made by DMP.	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

NorwayDMP (formerly NoMA / SLV)
United StatesFDA

English submissions

NorwayYes
United StatesYes

CTD accepted

NorwayYes
United StatesYes

eCTD accepted

NorwayYes
United StatesYes

Reliance pathway

NorwayAvailable
United StatesNone

Reference agencies

NorwayEMA (Centralised Procedure — mirrored automatically), EEA Member States (DCP / MRP), EU CMDh
United States—

Lead pathway (timeline & fees) — EU Centralised Procedure (mirrored nationally) · New Drug Application — 505(b)(1)

Pathway name

NorwayEU Centralised Procedure (mirrored nationally)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Norway210–300 days
United States304–365 days

Application fee

NorwayEUR 350,000
United StatesUSD 4,310,002

Annual renewal

NorwayEUR 130,000
United StatesUSD 416,734

Local representative

NorwayNot required
United StatesNot required

Local manufacturing

NorwayNot required
United StatesNot required

GMP inspection

NorwayRequired
United StatesRequired

MAH & local presence

Local entity required

NorwayNo
United StatesNo

Local responsible person

NorwayYes
United StatesYes

RP role

NorwayQPPV established in the EEA (any EEA member) per EU GVP Module I; QPPV is the contact for DMP pharmacovigilance. Norwegian-language pharmacovigilance literature monitoring required for products marketed in Norway. A Pharmacovigilance System Master File (PSMF) location must be declared.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Norway4 designations
United States6 designations

Examples

NorwayAccelerated Assessment (EMA CP), Conditional Marketing Authorisation (CMA), PRIME (Priority Medicines) +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

NorwayEU variations framework (Commission Regulation 1234/2008 as amended) — Type IA / IAIN (do-and-tell), Type IB (tell-wait-do), Type II (prior approval), Extensions and Article 61(3) notifications. DMP processes variations for nationally / DCP / MRP authorised products; EMA processes variations for centrally-authorised products with DMP receiving mirror decisions.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

NorwayStandard renewal at 5 years post first authorisation; subsequent unlimited validity unless DMP / EMA decides on safety grounds to require further renewal. CMAs renewed annually until conversion to full MA.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

NorwayEU pharmacovigilance framework (Directive 2010/84/EU and Regulation 1235/2010) implemented via Norwegian Medicines Act and DMP guidelines. EudraVigilance reporting mandatory; PSURs per EURD list submitted to EMA PSUSA. Norwegian Adverse Drug Reactions Register (Bivirkningsregisteret) operated by DMP. PRAC participation by DMP. Norwegian Med-Safety mobile app for patient reporting.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

NorwayAvailable
United StatesAvailable

Compassionate Use

NorwayAvailable
United StatesAvailable

Emergency Import

NorwayAvailable
United StatesAvailable

Parallel Import

NorwayPermitted
United StatesNot permitted

Clinical trials

CTA approval

NorwayRequired
United StatesRequired

Ethics approval

NorwayYes
United StatesYes

CTA timeline

Norway60–106 days
United States30–30 days

GCP standard

NorwayICH E6(R3) GCP; EU Clinical Trials Regulation 536/2014 (EU CTR); Norwegian Medicines Act and Regulation on Clinical Trials of Medicinal Products for Human Use
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

NorwayRegulated
United StatesFree pricing

Reference pricing

NorwayYes
United StatesNo

HTA required

NorwayYes
United StatesNo

HTA body

NorwayDMP (single-technology assessments — STA) and Norwegian Institute of Public Health / Folkehelseinstituttet — FHI (multi-technology assessments — MTA), under the Nye Metoder (New Methods) framework. Decisions for hospital medicines made by Beslutningsforum (the Decision Forum of the four Regional Health Authority CEOs); decisions for outpatient blue-prescription medicines made by DMP.
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding